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Abstract Purpose To evaluate blood loss during misoprostol-induced vaginal births and during
cesarean sections after attempted misoprostol induction.
Methods We conducted a prospective observational study in 101 pregnant women
indicated for labor induction; pre- and postpartum hemoglobin levels were measured
to estimate blood loss during delivery. Labor was induced by administering 25 µg
vaginal misoprostol every 6 hours (with a maximum of 6 doses). The control group
included 30 patients who spontaneously entered labor, and 30 patients who under-
went elective cesarean section. Pre- and postpartum hemoglobin levels were evaluated
using the analysis of variance for repeated measurements, showing the effects of time
(pre- and postpartum) and of the group (with and withoutmisoprostol administration).
Results There were significant differences between pre- and postpartum hemoglobin
levels (p < 0.0001) with regard to misoprostol-induced vaginal deliveries (1.6  1.4
mg/dL), non-induced vaginal deliveries (1.4  1.0 mg/dL), cesarean sections after
attempted misoprostol induction (1.5  1.0 mg/dL), and elective cesarean deliveries
(1.8  1.1 mg/dL). However, the differences were proportional between the groups
with and without misoprostol administration, for both cesarean (p ¼ 0.6845) and
vaginal deliveries (p ¼ 0.2694).
Conclusions Labor induction usingmisoprostol did not affect blood loss during delivery.
Resumo Objetivo Avaliar a perda sanguínea em partos vaginais induzidos com misoprostol, e
em cesáreas com tentativa prévia de indução do parto com misoprostol.
Métodos Realizou-se estudo prospectivo observacional com 101 gestantes com
indicação para indução do trabalho de parto, as quais foram avaliadas pela dosagem
de hemoglobina pré e pós-parto para estimativa da perda sanguínea no parto.
Procedeu-se à indução do trabalho de parto com misoprostol 25 µg, via vaginal, a
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Introduction
Misoprostol (15-deoxi-16-hydroxy-16-methyl prostaglandin
E1) is a synthetic analog of prostaglandin E1. This drug was
developed to treat and prevent gastrointestinal diseases, such
as peptic ulcers associated with nonsteroidal anti-inflamma-
tory drug use.1 Misoprostol exhibits various effects on the
uterine cervix, essentially acting on the extracellular matrix. In
addition, it relaxes the smooth muscles of the cervix and
facilitates its expansion, simultaneously facilitating the in-
crease of intracellular calcium and promoting mild uterine
contractions. These mechanisms enable gradual cervical
effacement and dilation concurrent with increased uterine
activity, which ensures successful labor induction in most
cases.2Misoprostol exhibits low perinatal morbidity and mor-
talitywhenadministeredat adoseof25µgevery6hours, and is
associated with a low risk of changes in uterine contractility
and hyperstimulation syndrome. However, at a dose of 50 µg
every 4 hours, the incidence of meconium release is of 21.5%.3
In the obstetric clinical practice, blood loss is generally
evaluated subjectively through visual assessment by the
professionals in charge of the pregnant woman, or through
the impact of the blood loss on the patient’s hemodynamic
stability, which varies among women and depends on their
reserves. Some studies have indicated that the clinical esti-
mation of postpartum bleeding has low scientific value.4,5
Estafan et al6 conducted a study to assess the accuracy of
visually estimated blood loss during vaginal births and
cesarean sections, correlating it with the postpartum de-
crease in hemoglobin. The clinical sensitivity to identify
excessive blood loss was of 12% and 13% for vaginal birth
and cesarean section respectively, and it was concluded that
clinical estimates of blood loss during childbirth are subjec-
tive and arbitrary. Another study showed a low correlation
between visual estimates of blood loss and perioperative
changes in hemoglobin among women who underwent
cesarean section. Thus, the analysis of hemoglobin dilution
(that is, the decrease in hemoglobin concentration) after
bleeding is a simple, inexpensive, and noninvasive means of
estimating blood loss.7 A study showed that blood loss after
oxytocin-induced labor ranged between 190 and 800 mL,
and that after misoprostol-induced labor, it ranged between
290 and 1200 mL, which was statistically significant. Fur-
thermore, the difference between the pre- and postpartum
hematocrit was significantly higher in the misoprostol-in-
duced labor group than in the oxytocin-induced labor
group.8 Although the studies indicate greater postpartum
blood loss after the misoprostol-induced labor, the effect of
smaller doses of misoprostol on blood loss is yet controver-
sial, because lower doses are associated with more gradual
changes in the cervix.
Therefore, this study aimed to evaluate blood loss in
pregnant women undergoing labor induced with 25 µg of
vaginal misoprostol every 6 hours by determining the differ-
ence between pre- and postpartum hemoglobin levels com-
pared with blood loss during non-induced births.
Methods
A prospective observational study was conducted between
January 2008 and January 2009 at the Maternidade Escola
Assis Chateaubriand. This studywas approved by the Research
Ethics Committee of the Universidade Federal do Ceará (UFC),
and the pregnant women provided their informed consent;
the study was conducted according to the guidelines of the
Helsinki Declaration regarding research involving human
subjects.
An open clinical trial was conducted to evaluate maternal
blood loss during childbirth by determining pre- and post-
partum maternal hemoglobin levels in patients with miso-
prostol-induced labor compared with those in patients with
non-induced labor. The study group included pregnant
women admitted to the obstetric pathology service at the
Maternidade Escola Assis Chateaubriandwhowere indicated
for elective labor induction and were anticipating delivery.
The control group included pregnant women with sponta-
neous labor that progressed to vaginal birth, and pregnant
women who had an indication for elective cesarean without
previous cesarean sections. The indications for elective ce-
sarean were the following: fetal growth restriction,
cada 6 horas, em um número máximo de 6 doses. O grupo controle foi composto por
30 pacientes que entraram em trabalho de parto espontaneamente, e por 30 pacientes
que se submeteram a cesárea eletiva. O estudo da hemoglobina, antes e depois do
parto, foi avaliado por ANOVA para medidas repetidas, no qual foi verificado o efeito do
tempo (pré e pós-parto) e o efeito do grupo (com e sem uso do misoprostol).
Resultados Existem diferenças significativas entre os níveis de hemoglobina pré e
pós-parto (p < 0,0001) nos partos vaginais induzidos pelo misoprostol (1,6  1,4 mg/
dL), nos partos vaginais não induzidos (1,4  1,0 mg/dL), nas cesáreas com tentativa
prévia de indução (1,5  1,0 mg/dL), e nas cesáreas eletivas (1,8  1,1mg/dL). Porém,
as diferenças foram proporcionais em ambos os grupos, ou seja, ocorreu diferença
tanto no grupo que fez uso do misoprostol quanto no grupo que não fez uso do
medicamento, tanto na cesárea (p ¼ 0,6845) quanto no parto vaginal (p ¼ 0,2694).
Conclusões A indução do parto com misoprostol não alterou a perda sanguínea
durante o parto.
Palavras-chave
► trabalho de parto
induzido
► misoprostol
► hemorragia pós-parto
► hemoglobina
► parto vaginal
Rev Bras Ginecol Obstet Vol. 39 No. 2/2017
Can the Induction of Labor with Misoprostol Increase Maternal Blood Loss? Souza et al.54
hypertensive disorders, breech position, and premature
rupture of membranes with an unfavorable Bishop score.
The inclusion criteria were as follows: indication for
elective labor induction (such as pre-eclampsia; HELLP syn-
drome (platelet level > 50,000/mm3); chronic hypertension;
prolonged pregnancy; pre-pregnancy diabetes mellitus;
gestational diabetes; heart disease; and thyroid disease);
gestation of a living fetus; vertex presentation; fetal weight
estimated byultrasound > 2,500 g and < 4,000 g, according
to the equation proposed by Hadlock et al;9 amniotic fluid
index (AFI) > 5 cm, except for cases of prematuremembrane
rupture, in which AFI < 5 cm was allowed; normal pre-
partum basal cardiotocography; Bishop score 6; and deter-
mination of pre- and postpartum hemoglobin levels. The
exclusion criteria were as follows: one prior cesarean deliv-
ery; prior uterine scarring from myomectomy; anomalous
presentation; evidence of altered fetal vitality (pre-partum
cardiotocography, fetal biophysical profile, and/or Doppler of
the umbilical artery); fetal growth restriction, with estimat-
ed fetalweight < 3 percentile for the gestational age, accord-
ing to the table proposed by Hadlock et al;10 multiple
gestation; genital bleeding; and tumor structure, malforma-
tions, and/or ulcerations in the vulvoperineal region and
birth canal. In all cases, the gestational age was determined
by the date of the last menstrual period, and confirmed by an
ultrasound performed in the first trimester.
Before induction, the pregnant women underwent basal
cardiotocography, vaginal digital examination by an inde-
pendent examiner to determine the Bishop score, obstetric
transabdominal ultrasound to assess fetal position, estima-
tion of fetal weight and AFI, andmeasurement of pre-partum
hemoglobin levels. Postpartum hemoglobin was measured
24 hours after delivery. Further, each pregnant woman was
administered a 25 µg vaginal misoprostol tablet. Cardioto-
cography and vaginal examinationwere repeated to reassess
the Bishop score every 6 hours, if the pregnant woman
reported pain, or if fetal distress was suspected. A different
obstetrician administered more tablets, up to a maximum
dose of 6 tablets, during this period, until at least 2 uterine
contractions lasting 30 seconds occurredwithin 10minutes.
Active labor was diagnosed when regular uterine activity
was associated with a cervix dilated > 3 cm and completely
effaced; at this time, the woman was transferred to the
obstetric center, where she was monitored until delivery.
If the pregnant woman did not experience labor within 6
hours after administering the last tablet, and the Bishop
score remained6, labor inductionwas considered a failure,
and a cesarean delivery was conducted. In the presence of
uterine tachysystole (5 contractions in 10 minutes), the
patient was instructed to rest in the left lateral decubitus
position, andwas rapidly hydratedwith 1,000 mL of lactated
Ringer’s solution for 30 minutes. If the condition persisted,
acute tocolysis was initiated with 20 mg of oral nifedipine.
When hyperstimulation syndrome (tachysystole associated
with fetal heart rate changes) was diagnosed, the pregnancy
was interrupted by cesarean section.
The sample size of each groupwas calculated based on the
difference between pre- and postpartum hemoglobin levels
in spontaneous vaginal births (1.3  1.1 mg/dL) and elective
cesarean sections (1.8  1.1 mg/dL) obtained from a previ-
ous study conducted by Estafan et al.6 The result was a
minimum of 28 cases in each group, with a significance level
of 5% and a test power of 80%, as proposed by Friendly11 for
analysis of variance (ANOVA) for repeated measurements.
The datawere entered into an Excel 2007 (Microsoft Corp.,
Redmond, WA, USA) spreadsheet, and analyzed using the
SPSS (SPSS Inc., Chicago, IL, USA) software. The data were
described using means, standard deviations (SDs), medians,
minimums, maximums, absolute frequencies (n), and rela-
tive frequencies (%). Comparison of means (paired Student’s
t-test) and medians (Mann–Whitney, chi-square, or Fisher’s
exact test) and Spearman’s rank correlation coefficient (r)
were used. Pre- and postpartum hemoglobin levels were
evaluated using ANOVA for repeated measurements, in
which the effects of time (the difference between pre- and
postpartum hemoglobin levels, regardless of misoprostol
use) and the effect of the group (the effect of misoprostol
use on hemoglobin levels)were analyzed. A significance level
(p) of < 0.05 was considered to be statistically significant.
Results
The studied group (misoprostol-induced labor) was consti-
tuted by 101 pregnant women: 53 vaginal deliveries, 46
cesarean sections, and 2 forceps deliveries. The control group
included 60 pregnant women: 30 spontaneous vaginal de-
liveries and 30 elective cesareans.
The mean maternal age was 24.5  6.2 years (14–40
years), and the mean number of pregnancies was 1.7  1.3
(1–8). Sixty pregnant women (59.4%) were nulliparous. The
mean gestational age during inductionwas 39.5  1.8 weeks
(34.8–42.1). Of the induced deliveries, 42.5% resulted from
prolonged pregnancies, and 24.7% from hypertensive disor-
ders during pregnancy.
The Spearman’s rank correlation coefficient between the
number of misoprostol doses and the Bishop score at the
beginning of the labor inductionwas significant (p ¼ 0.0059)
and negative (r ¼  0.27), that is, a significant and inversely
proportional but weak correlation was observed.
After misoprostol administration (misoprostol-induced
labor group), 55 patients (54.4%) progressed to vaginal
delivery, 2 of which were resolved using forceps, whereas
the other 46 patients (45.6%) underwent cesarean section.
The duration of labor progressing to vaginal delivery (55
cases)was up to 6 hours in 42 cases (76.4%) and6–12hours in
13 cases (mean, 268  144.4minutes). Oxytocinwas admin-
istered in 58.1% of the vaginal deliveries (32 cases), and the
mean duration was 180.7  162.8 minutes.
Cesarean sectionwas indicated for the following motives:
59% (27 cases) for failed induction, 21.7% (10 cases) for acute
fetal distress, 8.6% (4 cases) for functional dystocia, 8.6%
(4 cases) for hypertensive disorders, and only 2.1% (1 case)
for heavy vaginal bleeding.
Moreover, 27.7% of patients experienced nausea, 18.8%
developed emesis, and 4.9% and 2.9% of the women reported
hyperthermia and diarrhea respectively. Therewere no cases
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of uterine tachysystole or hyperstimulation syndrome. Of the
101 total cases, 10 (9.9%) newborns were admitted to the
neonatal intensive care unit (NICU), being 5 newborns
delivered vaginally and 5 delivered by cesarean section,
and no fetal or neonatal death was reported. ►Table 1
presents the perinatal outcomes of the 101 cases that were
evaluated.
When the variables were studied separately according to
the type of delivery (vaginal or cesarean), no significant
associations were found, except for the 1-minute Apgar
score < 7 (7.5% versus 21.7% for vaginal and cesarean deliv-
eries respectively, p ¼ 0.0433; ►Table 2).
The mean pre- and postpartum hemoglobin levels in the
group of mothers who delivered vaginally after induction
were 12.0  1.2 mg/dL and 10.4  1.8 mg/dL respectively,
with a postpartum decrease of 1.6  1.4 mg/dL. The mean
pre- and postpartum hemoglobin levels in the group of
mothers who had spontaneous vaginal delivery were
11.9  1.1 mg/dL and 10.5  1.4 mg/dL respectively, with
a postpartum decrease of 1.4  1.0 mg/dL (►Fig. 1).
The mean pre- and postpartum hemoglobin levels in the
group of mothers who had a cesarean section after attempted
induction were 12.0  1.2 mg/dL and 10.6  1.3 mg/dL
respectively, with a postpartum decrease of 1.5  1.0 mg/
dL. Finally, the mean pre- and postpartum hemoglobin levels
in the group of mothers who underwent elective cesarean
section were 12.3  1.5 mg/dL and 10.6  1.5 mg/dL respec-
tively, with a postpartum decrease of 1.8  1.1 mg/dL
(►Fig. 2).
Table 1 Perinatal outcomes of the 101 pregnant women
(misoprostol-induced labor group) included in the study
Perinatal outcome n %
Birth weight
1,500–2,499 g 4 4.0
2,500–3,999 g 90 89.1
4,000 g 7 6.9
Newborn weight
SGA 1 1.0
AGA 90 89.1
LGA 10 9.9
1-minute Apgar score
< 7 15 14.9
7 86 85.2
5-minute Apgar score
< 7 1 1.0
7 100 99.0
Capurro method, in weeks
0–37 weeks 9 8.9
37.1–40 weeks 62 61.4
40.1–41 weeks 17 16.8
41.1–42 weeks 13 12.9
Classification according to maturity
Preterm birth 6 5.9
Term 93 92.1
Post-term birth 2 2.0
Perinatal infection
Yes 12 11.9
No 89 88.1
Abbreviations: AGA, appropriate for gestational age; LGA, large for
gestational age; SGA, small for gestational age.
Table 2 Comparison of maternal and perinatal variables
according to the type of delivery in the misoprostol-induced
labor group
Type of delivery p
Vaginal† Cesarean
N % n %
Maternal age 1.0000
0–18 years 10 (18.9) 8 (17.4)
19–38 years 41 (77.4) 37 (80.4)
39 years 2 (3.8) 1 (2.2)
Number of gestations 0.2781
1 32 (60.4) 27 (58.7)
2 11 (20.8) 14 (30.4)
3 4 (7.5) 4 (8.7)
4 6 (11.3) 1 (2.2)
Parity 0.4219
0 36 (67.9) 35 (76.1)
1 11 (20.8) 8 (17.4)
2 3 (5.7) 2 (4.3)
3 0 (0.0) 1 (2.2)
4 3 (5.7) 0 (0.0)
Bishop score 0.5009
0 4 (7.5) 4 (8.7)
1 3 (5.7) 7 (15.2)
2 7 (13.2) 7 (15.2)
3 14 (26.4) 13 (28.3)
4 13 (24.5) 11 (23.9)
5 7 (13.2) 3 (6.5)
6 5 (9.4) 1 (2.2)
1-minute Apgar score 0.0433
< 7 4 (7.5) 10 (21.7)
7 49 (92.5) 36 (78.3)
5-minute Apgar score 0.4646
< 7 0 (0.0) 1 (2.2)
7 53 (100.0) 45 (97.8)
Notes: Chi-square test; †Two forceps deliveries were excluded.
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We assessed the effect of time (the difference in hemo-
globin levels during the pre- and post-partum periods,
independently of misoprostol induction) and if misoprostol
induction (groups with and without misoprostol induction)
would change the hemoglobin level differently (group ef-
fect). We observed a significant difference regarding the
effect of time in both types of delivery (p < 0.0001), but
not between the groups (p > 0.05). However, there were
significant differences between the pre- and postpartum
hemoglobin levels (p < 0.0001), but these differences were
proportional between the groups with and without
misoprostol administration, for both cesarean (p ¼ 0.6845)
and vaginal deliveries (p ¼ 0.2694;►Tables 3 and 4). For this
analysis, the two cases of delivery with forceps were not
considered, because this type of delivery is associated with
greater blood loss.
Discussion
In this study, the patients were administered 25 µg vaginal
misoprostol every 6 hours. Zieman et al12 performed thefirst
pharmacokinetic study of misoprostol using the same route,
and reported that the drug’s plasma concentration gradually
increased, reached the maximum level after 70–80 minutes,
and gradually decreased; the drug could be detected 6 hours
after administration. These authors observed that a 25 µg
dose was enough to trigger labor, but it did not increase the
frequency of changes in uterine contractility.
Fig. 1 Changes in hemoglobin levels during vaginal delivery. Fig. 2 Changes in hemoglobin levels during cesarean delivery.
Table 3 Hemoglobin levels during vaginal delivery
With
misoprostol
(n ¼ 53)†
Without
misoprostol
(n ¼ 30)
Ð
Effect of the group Effect
of Time
Hemoglobin Mean SD Mean SD
Vaginal birth p ¼ 0.2694 p < 0.0001
Pre-partum 12.0 1.2 11.9 1.1
Postpartum 10.4 1.8 10.5 1.4
Pre-partum minus postpartum 1.6 1.4 1.4 1.0
Abbreviation: SD, standard deviation.
Notes: Analysis of variance for repeated measurements; †Misoprostol-induced labor group;
Ð
control group.
Table 4 Hemoglobin levels during cesarean delivery
With misoprostol
(n ¼ 46)†
Without
misoprostol
(n ¼ 30)
Ð
Effect of
the group
Effect of
time
Hemoglobin Mean SD Mean SD
Cesarean p ¼ 0.6845 p < 0.0001
Pre-partum 12.0 10.2 12.3 10.5
Postpartum 10.6 10.3 10.6 10.5
Pre-partum minus postpartum 10.5 10.0 10.8 10.1
Abbreviation: SD, standard deviation.
Notes: Analysis of variance for repeated measurements; †misoprostol-induced labor group;
Ð
control group.
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Labor was effectively induced in 73.2% of cases, and
progressed to vaginal delivery in 54.4% of these cases. These
results are in line with other studies documenting the
effectiveness of misoprostol for inducing labor with a living
fetus. The success rate of the misoprostol labor induction
tends to be high compared with other methods of labor
induction.13,14
We observed a high rate of cesarean deliveries (45.5%),
which contradicts the majority of publications, in which the
range is between 3.1% and 38.9%.14–16 Sanchez-Ramos and
Kaunitz15 published ameta-analysis of the effect ofmisopros-
tol on the rate of cesarean sections, with an analysis of data
from 44 randomized clinical trials. They observed that the
overall rate of cesarean sections and the rate of cesarean
sections because of failed labor induction were significantly
low in patientswho receivedmisoprostol.We observed a high
rate of induction failure (59%), which may be because of the
low dose of misoprostol used, with a maximum of 6 tablets of
25-µg. In the study by Moraes Filho et al,17 the induction
failure rate was lower,7.5%. However, they used more doses
of misoprostol (200 µg), whereas we used up to 6 tablets (150
µg). Another risk factor for the high induction failure rate was
the high proportion of nulliparous women in our sample
(59.4%), as previously mentioned.18
Of the 101 cases, only 10 newborns (9.9%) required NICU
admission. In a systematic review, Crane et al19 assessed the
admission of newborns to the NICU in 9 studies involving a
total of 801 pregnant women who underwent vaginal miso-
prostol-induced labor; these authors reported 53 hospital-
izations (6.6%), a number that was lower than the one found
in our study.
Estafan et al6 evaluated blood loss using the postpartum
hemoglobin decrease, and reported means of 1.3 and 1.8 mg/
dL for spontaneous vaginal delivery and elective cesarean
section respectively. These values were similar to those ob-
tained for the control group in our study for vaginal delivery
and cesarean section without misoprostol (1.4 and 1.8 mg/dL
respectively). ElSedeek et al8 evaluated blood loss during
vaginal delivery in patients who were induced with 50 µg of
vaginal misoprostol and who were administered a second
dose of 50 µg 6 hours after the first if there were no
contractions. They observed that the mean blood loss mea-
sured using the postpartum hematocrit was of 6.90 mg/dL;
this value was higher than the one obtained in the present
study, in which 25 µg vaginal misoprostol was administered
every 6 hours (with a maximum of 6 doses), inducing a mean
postpartum hemoglobin decrease of 1.6 mg/dL after vaginal
delivery. This lower postpartum hemoglobin decrease was
probably associated with the lower dose of misoprostol used.
There are no studies in the literature that report the impact of
misoprostol induction on blood loss in patients who undergo
cesarean delivery after attempted induction.
We observed significant differences in hemoglobin levels
over time (pre- and postpartum) in both types of deliveries,
but not between the groups (with andwithout misoprostol).
However, the significant differences between the pre- and
postpartum hemoglobin levels were proportional between
the groups with andwithout misoprostol administration, for
both cesarean and vaginal deliveries. It can be concluded that
the postpartum hemoglobin decrease was statistically sig-
nificant in all groups, that is, hemoglobin levels provide an
effective estimation of blood loss during delivery. However,
the results of the effect of misoprostol-induced labor on
blood loss showed that misoprostol did not increase blood
loss during induced vaginal delivery if compared with its
effects during spontaneous vaginal delivery, and it did not
increase blood loss during cesarean sections after attempted
induction if compared with its effects during elective cesar-
ean sections. These findings may be because of the 25 µg
misoprostol administration, which facilitates more gradual
physiological changes in the cervix.
In conclusion, inducing labor with 25 µg vaginal miso-
prostol every 6 hours, with a maximum of 6 doses, did not
affect blood loss during the successfully induced vaginal
deliveries or during cesarean sections after attempted
induction.
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